516 related articles for article (PubMed ID: 10857214)
1. [Clinical behavior of serous and mucinous borderline tumors of the ovary with diploid DNA stem line. Follow-up studies after organ preserving and non-organ preserving therapy].
Mecke H; Börner-Klaussner B; Grosse G; Nadjari B; Hauptmann S
Zentralbl Gynakol; 2000; 122(5):274-9. PubMed ID: 10857214
[TBL] [Abstract][Full Text] [Related]
2. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
3. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
4. Surgery of borderline tumors of the ovary: retrospective comparison of short-term outcome after laparoscopy or laparotomy.
Ødegaard E; Staff AC; Langebrekke A; Engh V; Onsrud M
Acta Obstet Gynecol Scand; 2007; 86(5):620-6. PubMed ID: 17464594
[TBL] [Abstract][Full Text] [Related]
5. Fertility results and outcomes after pure laparoscopic management of advanced-stage serous borderline tumors of the ovary.
Kane A; Uzan C; Gouy S; Pautier P; Duvillard P; Morice P
Fertil Steril; 2010 Dec; 94(7):2891-4. PubMed ID: 20537629
[TBL] [Abstract][Full Text] [Related]
6. Clinical factors and biomarkers in ovarian tumors development.
Vrabie CD; Petrescu A; Waller M; Dina I
Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
[TBL] [Abstract][Full Text] [Related]
7. The role of DNA flow cytometry in borderline malignant ovarian tumors.
Lai CH; Hsueh S; Chang TC; Tseng CJ; Huang KG; Chou HH; Chen SM
Cancer; 1996 Aug; 78(4):794-802. PubMed ID: 8756374
[TBL] [Abstract][Full Text] [Related]
8. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma.
Kennedy AW; Hart WR
Cancer; 1996 Jul; 78(2):278-86. PubMed ID: 8674004
[TBL] [Abstract][Full Text] [Related]
9. Ovarian serous borderline tumors with invasive peritoneal implants.
Gershenson DM; Silva EG; Levy L; Burke TW; Wolf JK; Tornos C
Cancer; 1998 Mar; 82(6):1096-103. PubMed ID: 9506355
[TBL] [Abstract][Full Text] [Related]
10. Surgical staging, treatment, and follow-up of borderline tumors in different hospital categories: a prospective nationwide survey in Finland.
Kumpulainen S; Kuoppala T; Leminen A; Komulainen M; Puistola U; Sankila R; Mäkinen J; Grénman S
Acta Obstet Gynecol Scand; 2007; 86(5):610-4. PubMed ID: 17464592
[TBL] [Abstract][Full Text] [Related]
11. [Borderline ovarian tumors].
Ivanov S
Akush Ginekol (Sofiia); 2002; 42(1):23-5. PubMed ID: 11935694
[TBL] [Abstract][Full Text] [Related]
12. Results after laparoscopic management of serous borderline tumor of the ovary with peritoneal implants.
Deffieux X; Morice P; Camatte S; Fourchotte V; Duvillard P; Castaigne D
Gynecol Oncol; 2005 Apr; 97(1):84-9. PubMed ID: 15790442
[TBL] [Abstract][Full Text] [Related]
13. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
14. Epithelial ovarian tumors of borderline malignancy: long-term follow-up.
Casey AC; Bell DA; Lage JM; Fuller AF; Nikrui N; Rice LW
Gynecol Oncol; 1993 Sep; 50(3):316-22. PubMed ID: 8406194
[TBL] [Abstract][Full Text] [Related]
15. Results after conservative treatment of serous borderline tumors of the ovary with a micropapillary pattern.
Laurent I; Uzan C; Gouy S; Pautier P; Duvillard P; Morice P
Ann Surg Oncol; 2008 Dec; 15(12):3561-6. PubMed ID: 18820973
[TBL] [Abstract][Full Text] [Related]
16. [Clinicopathologic features of 234 cases with borderline ovarian tumors].
Ren J; Lou JY; Liu H; Wang P; Zhang JW; Yang KX; Wang HJ; Qie MR; Peng ZL
Zhonghua Fu Chan Ke Za Zhi; 2009 Feb; 44(2):116-20. PubMed ID: 19570422
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.
Gershenson DM; Deavers M; Diaz S; Tortolero-Luna G; Miller BE; Bast RC; Mills GB; Silva EG
Clin Cancer Res; 1999 Dec; 5(12):4053-8. PubMed ID: 10632339
[TBL] [Abstract][Full Text] [Related]
18. Is complete surgical staging necessary in patients with stage I mucinous epithelial ovarian tumors?
Cho YH; Kim DY; Kim JH; Kim YM; Kim KR; Kim YT; Nam JH
Gynecol Oncol; 2006 Dec; 103(3):878-82. PubMed ID: 16859736
[TBL] [Abstract][Full Text] [Related]
19. [Long-term studies of patients with borderline tumors of the ovaries].
Adam R; Reinhardt M; Thyselius D; Tulusan AH
Geburtshilfe Frauenheilkd; 1989 Dec; 49(12):1039-43. PubMed ID: 2558944
[TBL] [Abstract][Full Text] [Related]
20. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
